We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems Strong on Pipeline & Subscription Revenues
Read MoreHide Full Article
On Sep 5, we issued an updated research report on Pleasanton, CA-based Veeva Systems Inc (VEEV - Free Report) – a global provider of cloud software and data solutions for the life sciences industry. The company currently carries a Zacks Rank #3 (Hold).
Over the last 7 days, the Zacks Consensus Estimate for full-year 2017 earnings inched up by a penny to 36 cents per share, as most analysts revised their estimates upward.
Notably, after the impressive second-quarter fiscal 2017 results, Veeva Systems is poised on its pipeline that includes an exclusive range of products on its flagship Vault and Commercial cloud platforms. These products include Vault CTMS, Vault PromoMats Dam, CRM Engage Meeting and CRM Engage Webinar.
A glimpse at the second-quarter results reveals strong revenues and adjusted earnings, both of which beat the Zacks Consensus Estimate. Additionally, solid year-over-year subscription revenue growth has exclusively enhanced the recurring part of Veeva Systems’ revenue mix.
Notably, Veeva Systems initiated the sale of Vault Quality Management System (QMS) this June. This has been a key driver for the company as it has already signed multiple deals in this platform.
However, on the flip side, higher operating expenses have been a major dampener for margins. Further, cutthroat competition, sluggish macroeconomic conditions and a saturating life sciences market are likely to dent growth for Veeva Systems.
Stocks to Consider
Some better-ranked stocks in the broader medical space include Masimo Corporation (MASI - Free Report) , Quidel Corp. (QDEL - Free Report) and NuVasive Inc. . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Veeva Systems Strong on Pipeline & Subscription Revenues
On Sep 5, we issued an updated research report on Pleasanton, CA-based Veeva Systems Inc (VEEV - Free Report) – a global provider of cloud software and data solutions for the life sciences industry. The company currently carries a Zacks Rank #3 (Hold).
Over the last 7 days, the Zacks Consensus Estimate for full-year 2017 earnings inched up by a penny to 36 cents per share, as most analysts revised their estimates upward.
Notably, after the impressive second-quarter fiscal 2017 results, Veeva Systems is poised on its pipeline that includes an exclusive range of products on its flagship Vault and Commercial cloud platforms. These products include Vault CTMS, Vault PromoMats Dam, CRM Engage Meeting and CRM Engage Webinar.
VEEVA SYSTEMS-A Price
VEEVA SYSTEMS-A Price | VEEVA SYSTEMS-A Quote
A glimpse at the second-quarter results reveals strong revenues and adjusted earnings, both of which beat the Zacks Consensus Estimate. Additionally, solid year-over-year subscription revenue growth has exclusively enhanced the recurring part of Veeva Systems’ revenue mix.
Notably, Veeva Systems initiated the sale of Vault Quality Management System (QMS) this June. This has been a key driver for the company as it has already signed multiple deals in this platform.
However, on the flip side, higher operating expenses have been a major dampener for margins. Further, cutthroat competition, sluggish macroeconomic conditions and a saturating life sciences market are likely to dent growth for Veeva Systems.
Stocks to Consider
Some better-ranked stocks in the broader medical space include Masimo Corporation (MASI - Free Report) , Quidel Corp. (QDEL - Free Report) and NuVasive Inc. . Notably, all the three stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>